Breaking News
March 22, 2018 - HORIBA’s Microsemi CRP analyzer improves quality of care in emergency pediatric units, study shows
March 22, 2018 - Range of Vaginal Dryness Products Can Help Postmenopausal Women: Study
March 22, 2018 - Higher Dose Tx Deemed Safe in Pulmonary TB
March 22, 2018 - Diet soda associated with higher odds of diabetic retinopathy
March 22, 2018 - LSD reduces ‘sense of self’
March 22, 2018 - Vitamin D deficiency linked to metabolic syndrome in postmenopausal women
March 22, 2018 - Changes in the intestines may be responsible for reversal of diabetes after bariatric surgery
March 22, 2018 - iPads and Cancer; Clot Retrieval and Stroke: It’s PodMed Double T!
March 22, 2018 - Premature births linked to changes in mother’s bacteria
March 22, 2018 - Brain SPECT scans predict treatment outcomes in patients with depression
March 21, 2018 - Researchers succeed in integrating artificial organelles into cells of living organism
March 21, 2018 - Researchers discover ‘missing mutation’ in severe infant epilepsy
March 21, 2018 - Researchers develop statistics-based computational scheme to zoom in on brain function
March 21, 2018 - Verge joins Genomics England’s Discovery Forum industry partnership
March 21, 2018 - Trovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarabine (LDAC) in AML Trial
March 21, 2018 - Congenital Cardiac Cath Tx Often Strays from Guidelines
March 21, 2018 - Marked increase in cardiovascular risk factors in women after preeclampsia
March 21, 2018 - New app may help predict, track manic and depressive episodes in bipolar patients
March 21, 2018 - Discovery of genes could lead to development of novel therapies for EBV-related cancers
March 21, 2018 - High-fat, high-cholesterol diet depletes ranks of artery-protecting immune cells
March 21, 2018 - Research misconduct allegations shadow likely CDC appointee
March 21, 2018 - Most Breast Ca Patients Fail to Get Genetic Counseling
March 21, 2018 - Lopsided ear function can lead to lopsided brain development
March 21, 2018 - Acupuncture helps manage menopausal symptoms, review finds
March 21, 2018 - Motor skill training may contribute to reading skills in obese children
March 21, 2018 - Poor dental health may be related to increased diabetes risk
March 21, 2018 - Chronic opioid users at increased risk of complications after spinal fusion surgery
March 21, 2018 - Study uncovers potential therapeutic target against large family of parasites
March 21, 2018 - NSAID use linked to increased risk of atrial fibrillation
March 21, 2018 - Scientists develop brain “stethoscope” that can detect silent seizures
March 21, 2018 - New method predicts effects of global warming on disease
March 21, 2018 - Insurance Company Hurdles Burden Doctors, May Harm Patients
March 21, 2018 - Renal Transplant from HCV-Positive Donors Feasible
March 21, 2018 - Myelodysplastic syndrome: MedlinePlus Medical Encyclopedia
March 21, 2018 - Research reveals brain mechanism involved in language learning
March 21, 2018 - Many parents still hesitate to try early peanut introduction, survey finds
March 21, 2018 - Audiologist urges tinnitus sufferers facing ‘revolving door healthcare’ to seek support
March 21, 2018 - Study reveals impact of prostate cancer on wives and partners of sufferers
March 21, 2018 - ‘Almost a Miracle Drug’: What We Heard This Week
March 21, 2018 - Study shows NIH spent >$100 billion on basic science for new medicines
March 21, 2018 - Columbia researchers identify nerve cells that drive fruit fly’s escape behavior
March 21, 2018 - Sartorius Stedim Biotech selected by ABL Europe to supply single-use process technologies
March 21, 2018 - Increase in coffee consumption may help battle against colon cancer
March 21, 2018 - Hydrogel may accelerate healing of diabetic ulcers
March 21, 2018 - Dermira’s Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpoints
March 21, 2018 - DePuy Synthes introduces ACTIS Total Hip System for improving initial implant stability
March 21, 2018 - ‘Oh, It Was Nothing’
March 21, 2018 - Herbal drug kratom linked to salmonella illnesses, CDC says
March 21, 2018 - New optical point-of-care device could enhance screening for thyroid nodules
March 21, 2018 - FDA Expands Approval of Adcetris (brentuximab vedotin) for First-Line Treatment of Stage III or IV Classical Hodgkin Lymphoma in Combination with Chemotherapy
March 21, 2018 - Eosinophilic Esophagitis: Late Manifestation of Allergic March
March 21, 2018 - Signaling pathway involving the Golgi apparatus identified in cells with Huntington’s disease
March 21, 2018 - Quintupling inhaled steroid doses may not benefit children with asthma
March 21, 2018 - Study shows clear connection between cardiovascular fitness in middle age and dementia risk
March 21, 2018 - Premature babies have higher risks of health complications in Bangladesh
March 21, 2018 - Child’s temperament and parenting influence weight gain in babies
March 21, 2018 - Researchers find the heart to be capable of arrhythmia termination after local gene therapy
March 21, 2018 - Inhealthcare to provide digital infrastructure for NHS to help protect people from falls
March 21, 2018 - Flu Season Finally Slowing Down
March 21, 2018 - Mixed Results for Shorter DAPT in ACS Patients
March 21, 2018 - Scientists discover fish scale-derived collagen effective for healing wounds
March 21, 2018 - Genomics England announces new partnership to improve efficiency of next-generation sequencing analysis
March 21, 2018 - Adjuvant AC chemotherapy found to be effective in treating HRD-positive breast cancer patients
March 21, 2018 - Researchers identify new treatment targets for lung diseases using big data
March 21, 2018 - Kids see more women in science than five decades ago
March 21, 2018 - Research shows link between chronic fatigue syndrome and lower thyroid hormone levels
March 21, 2018 - Alzheimer’s disease on the rise
March 21, 2018 - Two Agents Equal as Pretreatment for Adrenal Tumor Surgery
March 21, 2018 - ‘Icebreaker’ protein opens genome for T cell development, researchers find
March 21, 2018 - Women in medicine shout #Metoo about sexual harassment at work
March 21, 2018 - Mother’s pre-pregnancy waist size may be linked to child’s autism risk
March 21, 2018 - Second hand marijuana smoke can cause serious damage
March 21, 2018 - International study shows benefits of using MRI at the start of prostate cancer diagnosis
March 20, 2018 - Santhera Reports Outcome of Exploratory Trial with Idebenone in PPMS Conducted at the NIH
March 20, 2018 - ECG Patch Ups At-Home Afib Diagnosis in mSToPS Trial
March 20, 2018 - ROS-scavenging nanozymes for anti-inflammation therapeutics
March 20, 2018 - Genomics England announces appointment of global genomics pioneer as first CEO
March 20, 2018 - Test flight at German Aerospace Center in Cologne demonstrates functionality of deficopter
March 20, 2018 - Music therapy helps treat combat-related psychological injuries in military personnel
March 20, 2018 - Innovative psychotherapeutic treatment protocol for obsessive-compulsive disorders
Trastuzumab No Benefit In Low-HER2 Breast Cancer

Trastuzumab No Benefit In Low-HER2 Breast Cancer

image_pdfDownload PDFimage_print

Action Points

  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
  • Treating high-risk breast cancer patients who tested low for HER2-receptor status with trastuzumab (Herceptin) provided no benefit in disease-free survival over women who are treated only with chemotherapy.
  • There were no statistically significant differences when looking at stratification by level of HER2-low status; by the number of positive lymph nodes; by hormone receptor status; or by type of chemotherapy.

SAN ANTONIO – Treating high-risk breast cancer patients who tested low for HER2-receptor status with trastuzumab (Herceptin) provided no benefit in disease-free survival over women who are treated only with chemotherapy, researchers reported here.

The 5-year overall invasive disease-free survival was 89.2% of women treated with chemotherapy alone compared with disease free survival of 89.6% in the women who were given chemotherapy and trastuzumab (P=0.90), reported Louis Fehrenbacher, MD, of Kaiser Permanente Northern California in Vallejo.

“We observed an overall survival of 95% in both arms of the trial,” he told MedPage Today at the 2017 San Antonio Breast Cancer Symposium.

Invasive disease events occurred in 134 women receiving just chemotherapy and 130 women getting chemotherapy plus trastuzumab during the 5 years of the study, Fehrenbacher reported at an SABCS press conference.

The trial was prompted by a finding in the 2005 National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31 study. Its main finding was an advantage for trastuzumab in women with HER2-receptor overexpression, but it also found a possible advantage in a small subset of women who were apparently misidentified as having overexpression but actually had low HER2 levels. Fehrenbacher and colleagues wanted to confirm whether this was real or some sort of fluke.

Apparently it was the latter.

“We usually don’t present studies with negative findings but these results are very important because we have many patients who are 1+ and 2+ and we have been wondering if we should be giving them a fairly expensive drug with side effect for a full year,” said Virginia Kaklamani, MD, of UT Health at San Antonio.

Why the current study – designated as NSABP B-47 – did not confirm the earlier result is not readily explained, Fehrenbacher said. He speculated that, in the earlier study, the HER2-low cases might actually have been HER2-positive. The findings in the original trial showed a trend toward benefit in the small group of patients, but those findings did not reach statistical significance.

To pursue the possible use of HER2-targeted agents in this expanded community of HER2-low breast cancer, Fehrenbacher and colleagues enrolled 3,270 women who were identified as having HER2-low breast cancer by immunohistochemistry (1+, 2+) — a level that would not normally be treated with trastuzumab.

They received chemotherapy at the choice of their provider, either doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 in four cycles every 3 weeks followed by 12 weeks of once-weekly paclitaxel; or docetaxel 75 mg/m2 plus cyclophosphamide 600 mg/m2 every 3 weeks for six cycles. The chemotherapy alone was randomly provided to 1,603 women; the chemotherapy plus trastuzumab was given to 1,599 women. There were 63 patients (1.9%) lost to follow-up.

“This will probably reduce the amount of trastuzumab being used, although it shouldn’t,” Fehrenbacher said. “There were probably a few cases in which the women had low or near HER2 levels but not quite the 3+ required. I think that the number of these patients being treated with trastuzumab is pretty low at the moment, but that number should go to zero. There was no benefit and there was toxicity, it is time consuming and it is expensive.”

He said that there were no statistically significant differences when looking at stratification by level of HER2-low status; by the number of positive lymph nodes; by hormone receptor status; or by type of chemotherapy. “There were no trends for efficacy observed,” he said.

Fehrenbacher said that the high survival was somewhat of a surprise: “These patients did extremely well. If you look at studies of outcomes over 30 years you see that there is an incremental improvement in the same stages of cancer decade after decade. Whether that is due to more lower stage diagnosis, less risk within the same stage, or maybe the treatment is better, the organization is better in providing care … it is hard to know why but it is very clear that outcomes in each stage are improving.”

Fehrenbacher disclosed relevant relationships with Genentech/Roche, CellDex, Abbvie, Macrogenitcs, Cascadian and Pfizer.

Kaklamani disclosed relevant relationships with Novartis and Pfizer.

  • Reviewed by
    Robert Jasmer, MD Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner


Tagged with:

About author

Related Articles